Showing 8321-8330 of 8692 results for "".
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- San Francisco Dermatologist Elected to AMA Board of Trusteeshttps://practicaldermatology.com/news/20140611-san_francisco_dermatologist_elected_to_ama_board_of_trustees/2459211/Jack Resneck Jr., MD, a dermatologist from San Francisco, CA, was elected to the American Medical Association (AMA) Board of Trustees. "I am honored to be elected to the AMA Board of Trustees," said Resneck. "Our AMA has an influential role to play in c
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- AAD Announces Donation of Melanoma Exposed Program from Bristol-Myers Squibbhttps://practicaldermatology.com/news/20140609-aad_announces_donation_of_melanoma_exposed_program_from_bristol-myers_squibb/2459214/Bristol-Myers Squibb donated its Melanoma Exposed™ program to the American Academy of Dermatology (AAD). The donation, provided through a charitable grant, will be used to increase public awareness of skin cancer—including melanoma, the deadliest form of skin cancer—and expand t
- Clinical Trials Designed to Block Autophagy in Multiple Cancers, Including Melanoma, Show Promisehttps://practicaldermatology.com/news/20140606-clinical_trials_designed_to_block_autophagy_in_multiple_cancers_including_melanoma_show_promise/2459217/
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutation
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- AAD Issues Statement on Drinkable Sunscreenhttps://practicaldermatology.com/news/20140523-aad_issues_statement_on_drinkable_sunscreen/2459231/